Format

Send to

Choose Destination
Semin Arthritis Rheum. 2010 Dec;40(3):210-4. doi: 10.1016/j.semarthrit.2010.03.001. Epub 2010 May 21.

Anakinra's efficacy is variable in refractory gout: report of ten cases.

Author information

1
Rheumatology Division, Weill Cornell Medical College, Hospital for Special Surgery, New York, NY, USA. chenk@hss.edu

Abstract

OBJECTIVES:

To evaluate the efficacy of anakinra for patients with acute gout.

METHODS:

We reviewed the charts of 10 patients who received anakinra for urate crystal-induced arthritis at the Hospital for Special Surgery since 2007. Demographic information, comorbidities, short-term treatment outcomes, and subsequent flares were reviewed.

RESULTS:

Patients in our study had a high prevalence of comorbidities. All patients received corticosteroids before anakinra treatment. The mean number of anakinra injections was 3.2 per patient (100 mg subcutaneously per day). Six patients had a good response. Three patients had a partial response and 1 patient had no response. Nine patients had documented recurrent flares after discontinuing anakinra (ranging from 3 to 45 days after).

CONCLUSION:

Anakinra is a therapeutic option for patients with acute urate crystal-induced arthritis who do not respond to or have a contraindication to traditional treatments. Although a short course of anakinra resulted in favorable outcomes for some of our patients, response rates were poorer in our study than in previously published reports, and relapses were common.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center